01297nas a2200145   4500000000100000008004100001260001300042100001500055700001500070700001500085245006800100300001200168520095300180020001801133       2023                            d  bElsevier1 aMennuru NB1 aBirudala R1 aBirudala G00aPathogenesis, clinical manifestations, and treatment of leprosy  a609-6153 a<p>The bacillus&nbsp;<em>Mycobacterium leprae</em>&nbsp;causes leprosy, a chronic granulomatous disease. Skin and nerves are primarily affected and still endemic in various regions of the planet. It is important to note that the patient’s immune status can influence the disease’s clinical presentation. Leprosy is a disease that is associated with physical impairment and social exclusion. Patients with at least one of the&nbsp;World Health Organization’s cardinal signs—hypopigmented or erythematous macules with sensory loss, thickened peripheral nerves, or positive acid-fast smear or skin biopsy with loss of adnexa at affected sites—will have their diagnosis made based on clinical findings alone.</p>

<p>Rifampicin, clofazimine, and dapsone are used to treat leprosy. It is necessary to use one of two main regimens based on whether the patient has paucibacillary or multibacillary disease</p>

<ul>
</ul>

<p>&nbsp;</p>
  a9780323857307